Pradaxa Sales Data
| Rank 88 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Pradaxa U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 88 ( 4) |
$200,697 | -0.53% | 819 | -3.53% |
| Q3 2013 | 84 (11) |
$201,776 | -2.91% | 849 | -11.19% |
| Q2 2013 | 73 ( 2) |
$207,826 | -3.34% | 956 | -2.75% |
| Q1 2013 | 75 (4) |
$215,003 | 4.76% | 983 | -0.20% |
| Q4 2012 | 79 (4) |
$205,238 | -1.83% | 985 | -4.18% |
| Q3 2012 | 75 (1) |
$209,063 | 3.84% | 1,028 | 4.58% |
| Q2 2012 | 76 (5) |
$201,327 | 0.13% | 983 | -2.77% |
| Q1 2012 | 81 (4) |
$201,065 | 5.13% | 1,011 | 6.53% |
| Q4 2011 | 85 (7) |
$191,260 | 16.27% | 949 | 16.30% |
| Q3 2011 | 92 ( ) |
$164,496 | n/a | 816 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
